Table 2.
Demographic and Clinical Characteristics of Subject Groups (treatment-naïve group, bisphosphonate group, denosumab group, and teriparatide group) at Baseline. Data are expressed as the mean ± standard deviation or the number (%) of patients. P1NP and TRACP-5b are expressed as median values.
| Naïve N = 97 |
Bisphosphonates N = 42 |
Denosumab N = 31 |
Teriparatide N = 34 |
P-value | |
|---|---|---|---|---|---|
| Age (years) | 74.4 ± 13.1 | 73.4 ± 13.9 | 69.6 ± 19.1 | 68.9 ± 16.0 | 0.407 |
| Female, n (%) | 82 (84.5) | 36 (85.7) | 25 (83.3) | 31 (91.2) | 0.819 |
| Body mass index (kg/m2)a | 21.3 ± 3.5 | 20.6 ± 4.6 | 19.8 ± 4.5 | 19.5 ± 3.8 | 0.088 |
| Bone mineral density T-score | |||||
| Lumbar spine | −2.85 ± 1.09 | −2.39 ± 1.25 | −1.70 ± 1.30 | −2.78 ± 1.24 | P < 0.001 |
| Total hip | −2.66 ± 0.84 | −2.25 ± 0.98 | −2.48 ± 0.88 | −2.55 ± 1.03 | 0.142 |
| Femoral neck | −3.23 ± 0.85 | −2.75 ± 1.10 | −2.86 ± 0.95 | −2.92 ± 1.14 | 0.145 |
| Duration of previous treatment (M) | – | 29 | 39 | 16 | P < 0.001 |
| Prior vertebral fracture, n (%) | 35 (36.1) | 13 (31.0) | 9 (30.0) | 15 (44.1) | 0.543 |
| Prior non-vertebral fracture at >45 years of age, n (%) | 23 (23.6) | 10 (23.8) | 6 (20.0) | 12 (35.3) | 0.512 |
| Prior fractures of both vertebrae and non-vertebrae, n (%) | 7 (7.2) | 2 (4.8) | 3 (10.0) | 4 (11.8) | 0.659 |
| Concomitant active vitamin D, n (%) | 51 (52.6) | 21 (50.0) | 16 (51.6) | 20 (58.8) | – |
| Glucocorticoid use, n (%) | 8 (8.2) | 8 (19.0) | 11 (35.5) | 8 (23.5) | 0.004 |
| Median serum total P1NP (IQR), μg/L | 73.3 (18.0–495) |
25.6 (12.2–88.9) |
23.6 (9.5–373) |
98.9 (39.8–363) |
P < 0.001 |
| Median serum TRACP-5b (IQR), mU/dL | 587.0 (222–1370) |
308.5 (121–771) |
243.50 (81–1020) |
531.0 (262–1500) |
P < 0.001 |
| Serum albumin, g/dL | 4.14 ± 0.38 | 4.01 ± 0.31 | 4.08 ± 0.32 | 4.07 ± 0.30 | 0.309 |
| Serum-corrected calcium, mg/dL | 9.24 ± 0.35 | 9.38 ± 0.45 | 9.29 ± 0.53 | 9.31 ± 0.36 | 0.303 |
| Serum phosphorus, mg/dL | 3.57 ± 0.56 | 3.45 ± 0.44 | 3.72 ± 0.65 | 3.76 ± 0.56 | 0.097 |
| eGFR, mL/min/1.73 m2 | 67.9 ± 25.6 | 64.9 ± 17.7 | 64.3 ± 27.4 | 70.3 ± 20.1 | 0.621 |
| 25OHD, ng/mL | 15.9 ± 6.21 | 16.7 ± 5.92 | 18.4 ± 8.81 | 13.5 ± 5.09 | 0.017 |
| ucOC, ng/mL | 9.10 ± 8.43 | 2.87 ± 2.31 | 1.45 ± 1.29 | 9.50 ± 6.26 | P < 0.001 |
| Intact PTH, μg/mL | 59.1 ± 52.1 | 43.4 ± 19.9 | 49.2 ± 44.2 | 50.4 ± 32.0 | 0.188 |
P1NP, procollagen type 1 N-terminal propeptide; IQR, inter-quartile range; TRACP-5b, tartrate-resistant acid phosphatase isoform 5b; eGFR, estimated glomerular filtration rate; 25OHD, 25-hydroxyvitamin D; ucOC, undercarboxylated osteocalcin; intact PTH, intact parathyroid hormone.
Differences between the groups were determined by ANOVA or Fisher's exact test.
a
Calculated as weight in kilograms divided by the square of height in meters.